DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration Rockville MD 20857

Re: Ray Threaded Fusion Cage Docket No. 97E-0087

Video of 1000

The Honorable Q. Todd Dickinson Deputy Assistant Commissioner for Patent Policy and Projects Office of the Assistant Commissioner for Patents U.S. Patent and Trademark Office Crystal Park Building 2, Suite 919 Washington, DC 20231

Dear Commissioner Dickinson:

This is in regard to the patent term extension application for U.S. Patent No. 4,961,740 filed by United States Surgical Corporation under 35 U.S.C. § 156. The patent claims the medical device Ray Threaded Fusion CageTM, premarket approval application PMA P950019.

In the October 13, 1998, issue of the Federal Register (63 Fed. Reg. 54719), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before April 12, 1999, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson, Director Health Assessment Policy Staff

Office of Health Affairs

Neil D. Gershon, Esq. CC:

United States Surgical Corporation

150 Glover Avenue

Norwalk, CT 06850

97E-0087

LETH

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service Food and Drug Administration

1784 Memorandum 31

APR 23 1999

Date:

From: Brian J. Malkin, Associate Director for Patents and Hearings

Health Assessment Policy Staff (HFY-20)

Subject: Patent Term Restoration Application

for Ray Threaded Fusion Cage[™]

To: Dockets Management (HFA-305)

Attached is a letter to the Patent Term Office for the above mentioned drug under the Docket Number 97E-0087 stating that this particular patent is eligible for regulatory review. The Patent Number is 4,961,740. Please place this recent correspondence in the appropriate file.

If you have any questions, please contact me at 827-6620. Thank you for your assistance.